By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience
The number of insurance denials for life-saving hepatitis C drugs among patients with both private and public insurers remains high across the United States. Private insurers had the highest denial rates, with 52.4 percent of patients denied coverage, while Medicaid denied 34.5 percent of patients and Medicare denied 14.7 percent.
By screening 250 user reviews and comments for a once popular -- but proven inaccurate -- mobile app claiming to change your iPhone into a blood pressure monitor, Johns Hopkins researchers have added to evidence that a high “star rating” doesn’t necessarily reflect medical accuracy or value.
Embolization -- the use of various techniques to cut off the blood vessels that feed tissue growth -- has gained traction over the past few decades to treat cancerous tumors, and one specific version is gas embolotherapy. During this process, the blood supply is cut off using acoustic droplet vaporization, which uses microscopic gas bubbles induced by exposure to ultrasonic waves. Researchers have discovered that these bubbles could also be used as potential drug delivery systems. The researchers report their findings this week in Applied Physics Letters.
Researchers share perspective about Clinical Trials in a Dish (CTiD), a novel strategy that bridges preclinical testing and clinical trials.
A new study finds stable patients on blood thinners may not need to get their blood drawn as often as they currently do. Researchers were able to increase the number of people waiting longer than five weeks in between their INR blood draws from less than half (41.8%) to more than two-thirds (69.3%).
Researchers have gained new insights into the virus that causes hepatitis B – a life-threatening and incurable infection. The discovery reveals previously unknown details about the shell of the vigenetic blueprint and could lead to new drugs to treat the infection.
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease.
This month's tip sheet from Fred Hutch includes information about cancer care delivery and costs, partnering with Microsoft, understanding/changing cancer's genetics and a Mt. Everest climb for cancer research fundraising. To pursue any of these story ideas, please contact the individual listed for each.
The latest research and features in cell biology in the Cell Biology News Source
Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
Immunosuppressed patients with sepsis appear more likely to die if they are treated in a hospital caring for a relatively small number of these patients, according to new research published online in the Annals of the American Thoracic Society.
A new approach pioneered at the University of Pennsylvania’s Abramson Cancer Center may provide a new path towards treating Acute Myeloid Leukemia (AML) with CAR T cells.
UT Southwestern Medical Center geneticist Dr. Helen Hobbs is the 2018 recipient of the Institut de France Grand Prix Scientifique.
New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common – and deadliest – type of brain tumor. The findings, published in Science Translational Medicine, offer hope that the drug may one day be used in patients with glioblastoma and improve poor survival rates.
Researchers at the University of Pennsylvania’s Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system.
Saint Louis University researcher Gina Yosten, Ph.D is pursuing solutions for people with diabetes who are at risk of life-threatening drops in blood sugar.
Hematopoietic Stem Cells (HSCs) give rise to blood and immune cells of the body, and are therefore essential for our survival. They are in a dormant state, but whenever new blood needs to be formed, such as after blood loss or chemotherapy, they are rapidly activated to compensate for the loss. After completing their mission, they need to go back to their dormant state. The group of Manuela Baccarini at the Max F. Perutz Laboratories, a joint venture of the University of Vienna and the Medical University of Vienna, has now shown how intracellular signalling can safeguard this delicate balance between activation and dormancy. Their results are published in the prominent journal Cell Stem Cell.
National guidelines assume that all patients who’re diagnosed with clinical sepsis in an emergency department will be admitted to the hospital for additional care, but new research has found that many more patients are being treated and released from the ED for outpatient follow-up than previously recognized.
With the recently announced FDA approval of Kymriah to treat adults with lymphoma, the University of Michigan Rogel Cancer Center is the first center in Michigan to offer all currently available CAR T-cell therapies.
James Isbon was the second patient in the United States and the seventh in the world to have an aneurysm, or bulge, in the aortic arch above his heart repaired in a novel and minimally invasive way.
Considering the size of red blood cells, a new model for blood flow sheds light on why blood sometimes prefers some vessels over others.
The VF has produced a new video as part of its Vasculitis Awareness Month campaign, that features patients sharing the one thing they wished people knew about their disease.
Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers.
A new study by researchers from the University of Chicago Medicine shows that bacterial signals are crucial to the development of a precursor condition to leukemia, which can be induced by disrupting the intestinal barrier or by introducing a bacterial infection.
Seattle Cancer Care Alliance (SCCA) recently opened the Hematologic Malignancy Genetics Clinic, which provides personalized risk assessment and follow-up care for adult patients and family members who may be at increased risk for developing hematologic malignancies due to an underlying genetic cause.
The UAB-led clinical trial intends to provide multiple myeloma patients a treatment plan that eradicates their disease and enables them to live a life without ongoing treatment.
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.
National Comprehensive Cancer Network releases NCCN Guidelines for Patients: AML
Click here to go directly to the Cancer News Source
The VF produced a new video called "Connect the Dots" especially for Vasculitis Awareness Month 2018. The short, animated video reminds medical professionals to "Think Vasculitis" when they have a patient exhibiting a cluster of chronic, unremarkable symptoms that don't respond to traditional treatment.
• This study was the first to test a form of intermittent fasting, known as early time-restricted feeding, in humans. • The study shows for the first time in humans that the benefits of intermittent fasting are not due solely to eating less. • Practicing intermittent fasting has intrinsic benefits regardless of what you eat.
A Johns Hopkins study found that physicians who use stigmatizing language in their patients’ medical records may affect the care those patients get for years to come.
TAMPA, Fla. – Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient’s own immune cells to fight cancer. The Food and Drug Administration has approved CAR T therapy products for adults with diffuse large B-cell lymphoma and pediatric and young adults suffering from acute lymphoblastic leukemia.
New research from the Stowers Institute for Medical Research reveals that a DNA regulatory element within the Hoxb cluster globally mediates signals to the majority of Hoxb genes to control their expression in blood-forming stem cells.
The Dependable Point-of-Care Blood Analyzer! Excellent Performance and Value now available in the EU.
NCCN and MPN Research Foundation present Know What Your Doctors Know: Myeloproliferative Neoplasms (MPN), a free webinar for experts to provide information and answer questions on diagnosis and treatment options.
The VF announces the launch of Vasculitis Awareness Month 2018 that runs through May. The VF is holding special webinars, providing educational materials, and featuring other resources to inform both the patient and medical communities about autoimmune vasculitis.
Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal gammopathy of undetermined significance (MGUS).
The addition of a nurse-led intervention for hypertension management to health insurance coverage was more effective in lowering blood pressure (HPB) than the provision of health insurance alone in the Sub-Saharan country of Ghana, a region of Africa where HPB is rampant, according to a study publishing online on May 1 in the journal PLOS Medicine.
Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are before the therapy is administered.
Notre Dame researchers found that this communication varies across the colony and suggest that this bacterium may develop protective behaviors that contribute to its ability to tolerate some antibiotics.
Physician scientist Christopher Seymour talks about his experience treating sepsis patients and his new study indicating that quicker treatment improves survival odds.
Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
A study in today’s issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers at Albert Einstein College of Medicine, Montefiore Health System, the Fire Department of the City of New York (FDNY) and Memorial Sloan Kettering Cancer Center.
A research team from Queen’s University Belfast, in collaboration with an international team of experts, have made ground-breaking insights into how inflammatory diseases work.
Doctors at the University of Illinois Hospital have cured seven adult patients of sickle cell disease, an inherited blood disorder primarily affecting the black community, using stem cells from donors previously thought to be incompatible, thanks to a new transplant treatment protocol.
A new study at Washington University School of Medicine in St. Louis shows an investigational drug prevents graft-versus-host disease, a dangerous side effect of stem cell transplantation.
Investigators at Rutgers Cancer Institute have discovered that some mutations detected in comprehensive, clinical genome sequencing of patients with solid tumors do not originate from cancer cells, but arise from mutated hematopoietic cells that infiltrate the tumor microenvironment. The findings, they say, have direct implications for cancer patients, specifically in accurately interpreting their molecular testing results and ensuring that treatment is focused on somatic tumor-specific mutations.
The latest research, experts and features in Public Health in the Public Health News Source
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right